NCI Study Targets Barriers to Colorectal Cancer Screening

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

BETHESDA, Md-National Cancer Institute researchers have begun the first national study aimed at identifying barriers to screening for colorectal cancer. Investigators from the Centers for Disease Control and Prevention and the Health Care Financing Administration are collaborating in the effort.

BETHESDA, Md—National Cancer Institute researchers have begun the first national study aimed at identifying barriers to screening for colorectal cancer. Investigators from the Centers for Disease Control and Prevention and the Health Care Financing Administration are collaborating in the effort.

Questionnaires are being sent to a representative sample that includes 1,389 primary care physicians, 1,042 medical specialists, and 323 health plan medical directors. Researchers are seeking data on factors that may affect the use of screening and diagnostic follow-up in community practices. The study aims to assess the knowledge of physicians and their attitudes, practice patterns, and health plan guidelines for providing or promoting colorectal cancer screening.

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Related Content